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Abstract
AIM
To cure typically life-threatening esophagogastric 
anastomosis in rats, lacking anastomosis healing and 
sphincter function rescue, in particular. 
METHODS
Because we assume esophagogastric fistulas represent 
a particular NO-system disability, we attempt to 
identify the benefits of anti-ulcer stable gastric 
pentadecapeptide BPC 157, which was in trials for 
ulcerative colitis and currently for multiple sclerosis, 
in rats with esophagocutaneous fistulas. Previously, 
BPC 157 therapies have promoted the healing of 
intestinal anastomosis and fistulas, and esophagitis and 
gastric lesions, along with rescued sphincter function. 
Additionally, BPC 157 particularly interacts with the NO-
system. In the 4 d after esophagogastric anastomosis 
creation, rats received medication (/kg intraperitoneally 
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ORIGINAL ARTICLE
Esophagogastric anastomosis in rats: Improved healing by 
BPC 157 and L-arginine, aggravated by L-NAME
Basic Study
Zeljko Djakovic, Ivka Djakovic, Vedran Cesarec, Goran Madzarac, Tomislav Becejac, Goran Zukanovic, 
Domagoj Drmic, Lovorka Batelja, Anita Zenko Sever, Danijela Kolenc, Alen Pajtak, Nikica Knez, Mladen Japjec, 
Kresimir Luetic, Dinko Stancic-Rokotov, Sven Seiwerth, Predrag Sikiric
once daily: BPC 157 (10 µg, 10 ng), L-NAME (5 mg), or 
L-arginine (100 mg) alone and/or combined or BPC 157 
(10 µg, 10 ng) in drinking water). For rats underwent 
esophagogastric anastomosis, daily assessment 
included progressive stomach damage (sum of the 
longest diameters, mm), esophagitis (scored 0-5), weak 
anastomosis (mL H2O before leak), low pressure in 
esophagus at anastomosis and in the pyloric sphincter 
(cm H2O), progressive weight loss (g) and mortality. 
Immediate effect assessed blood vessels disappearance 
(scored 0-5) at the stomach surface immediately after 
anastomosis creation. 
RESULTS
BPC 157 (all regimens) fully counteracted the perilous 
disease course from the very beginning (i.e. , with 
the BPC 157 bath, blood vessels remained present 
at the gastric surface after anastomosis creation) 
and eliminated mortality. Additionally, BPC 157 treat-
ment in combination with L-NAME nullified any effect 
of L-NAME that otherwise intensified the regular 
course. Consistently, with worsening (with L-NAME 
administration) and amelioration (with L-arginine), 
either L-arginine amelioration prevails (attenuated 
esophageal and gastric lesions) or they counteract 
each other (L-NAME + L-arginine); with the addition 
of BPC 157 (L-NAME + L-arginine + BPC 157), there 
was a marked beneficial effect. BPC 157 treatment for 
esophagogastric anastomosis, along with NOS-blocker 
L-NAME and/or NOS substrate L-arginine, demonstrated 
an innate NO-system disability (as observed with 
L-arginine effectiveness). BPC 157 distinctively affected 
corresponding events: worsening (obtained with 
L-NAME administration that was counteracted); or 
amelioration (L-arginine + BPC 157-rats correspond to 
BPC 157-rats).
CONCLUSION
Innate NO-system disability for esophagogastric 
anastomoses, including L-NAME-worsening, suggests 
that these effects could be corrected by L-arginine and 
almost completely eliminated by BPC 157 therapy. 
Key words: Esophagogastric anastomosis; L-NAME; 
Aggravation; BPC 157; L-arginine; Curative treatment; 
Rats
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Core tip: In rats underwent esophagogastric anas-
tomosis, BPC 157 (given intraperitoneally or in drinking 
water) fully counteracted an otherwise serious disease 
course since very beginning (i.e. , with BPC 157 bath 
blood vessels remained present at the gastric surface 
after anastomosis creation) and eliminated mortality. 
Additionally, BPC 157 treatment, along with L-NAME, 
nullified any effect of L-NAME that otherwise intensi-
fied the regular course. Consistently, with worsening 
(with L-NAME administration) and amelioration (with 
L-arginine), either L-arginine-amelioration prevails (i.e. , 
esophageal and gastric lesions are attenuated) or they 
counteract each other (L-NAME + L-arginine), an effect 
which is further reversed toward a marked beneficial 
effect with the addition of BPC 157 (L-NAME + L-arginine 
+ BPC 157).
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INTRODUCTION
We acknowledged curative treatment of esophagogastric 
anastomosis in rats with stable gastric pentadecapeptide 
BPC 157 (an anti-ulcer peptide stable in human gastric 
juice), as a novel mediator of Robert’s cytoprotection 
that was effective in the entire gastrointestinal tract, 
which was originally tested in clinical trials for ulcerative 
colitis and multiple sclerosis[1-7]. Additionally, BPC 157 
treatment of esophagogastric anastomosis along 
with a NO-synthase (NOS) blocker, L-NAME, and/or 
NOS substrate L-arginine would evidence an innate 
NO-system disability, and investigate the effect on 
the corresponding worsening (obtained with L-NAME 
administration) or amelioration (due to L-arginine).
In general, in the curative treatment of esophageal 
cancer, the most feared complication is the highest rate 
of anastomotic leakage[8] compared with anastomoses 
involving other parts of the gastrointestinal tract[9]. 
Likely, BPC 157 exhibits some favorable effects 
for esophagogastric anastomosis healing. Together, 
intestinal anastomosis[10-14] and fistulas[15-20] healing, 
esophagitis and gastric lesion healing, alongside with 
rescued sphincter function[10,11,17,18,20-25] could certainly 
improve the possible curative peptides therapy for 
rat esophagogastric anastomosis. Until now, only to 
improve anastomosis healing, tested were keratinocyte 
growth factor-2 (KGF-2) (shown to be ineffective given 
intraperitoneally)[26] (regardless to therapeutic efficacy 
of a mutant of KGF-2 on trinitrobenzene sulfonic acid-
induced rat model of Crohn’s disease[27]) and FGF-beta 
(effective given topically[28]). 
Additionally, unlike other anastomoses, the esopha-
gogastric anastomosis should not only resist leakage, it 
should maintain some “sphincter” function at the anas-
tomosis site, a point that thus far been unappreciated for 
standard peptide growth factors[26,28]. As a result, these 
standard peptide growth factors[26,28] only support 
the particular perilous course of the esophagogastric 
anastomosis and show little improvement in rats[29,30]. 
On the other hand, these combined BPC 157 effects 
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may be more useful for both anastomosis healing and 
sphincter function rescue[10-14,17,18,20-25]. As a result, 
the esophagogastric anastomosis healing should both 
resist leakage and maintain some “sphincter” function 
at the anastomosis site. These effects may be the 
maintained esophageal and stomach integrity, and they 
counteracted the development of both esophagitis and 
gastric lesions. 
Another point may be the perilous effect of ische-
mia[31-33]. To accelerate anastomosis healing, several 
studies implicate the positive effect of the induced 
angiogenesis that follows partial devascularization of 
the stomach after a certain period (i.e., two-week 
period)[34-37]. As a very active cytoprotective agent, 
BPC 157[6], confronted with an injurious course, rapidly 
induces strong endothelium protection[38] as with 
standard cytoprotective agents[39], but it has a more 
prominent angiogenic effect[40] that may significantly 
contribute to healing in esophagogastric anastomosis. 
Finally, with BPC 157 designated as a “wound healing 
therapy”[1-7], these were attributed to the stimulation 
of the early growth response-1 (EGR1) gene and its 
co-repressor nerve growth factor 1-A binding protein-2 
(NAB2), which affected cytokine and growth factor 
generation and, thereby, early extracellular matrix 
(collagen) and blood vessel formation[41]. As a result, 
a particular feedback-process for the simultaneous 
healing of different tissues was suggested, leading to 
both internal and external wound healing, anastomosis 
and fistulas[1-7]. Others correlated the BPC 157 beneficial 
effects with the activation of a cellular FAK-paxillin 
signaling pathway and, subsequently, demonstrated 
that BPC 157 dose- and time-dependently increased 
the expression of growth hormone receptor, Janus 
kinase 2, which belongs to the downstream signal 
pathway of growth hormone receptor and may interact 
with other molecular pathways[42-44]. 
Additionally, BPC 157, based on the beneficial 
activities noted[1,5,7,17,18,19,45-51], would have particular 
effects on the NO-system (for review[1-7]), as observed 
in different models and species[1,5,7,17,18,19,45-51], but 
it has not previously been tested in anastomosis 
healing. Likewise, the NO-system plays a particular 
role in the gastrointestinal lesion healing[1]. It has been 
more frequently investigated in gastric lesions[1] than 
in esophagitis lesions[18,52]; despite inconsistencies, 
L-arginine has a beneficial effect, while L-NAME has 
an ulcerogenic effect[1], and they have not been inves-
tigated in esophagogastric anastomosis. 
For practical purposes, the stable gastric pentade-
capeptide BPC 157, was given daily, intraperitoneally or 
orally, in drinking water, using the previous efficacious 
regimens[7,15-25]. In addition to these effects, the possible 
simultaneous healing (stable gastric pentadecapeptide 
BPC 157, along with both NOS-blockade, L-NAME, 
and NOS-substrate L-arginine application[1]) would 
define the esophagogastric anastomosis healing, 
define esophagitis and gastric defects healing, rescue 
“sphincter” pressure at the site of anastomosis and 
preserve pyloric sphincter pressure, as a new NO-
system related phenomenon.
MATERIALS AND METHODS
Animals
Wistar Albino male rats (200 g b.w.) were randomly 
assigned to the experiments (at least 10 animals per 
experimental group). All experiments were approved 
by the Local Ethics Committee. Furthermore, all 
experiments were performed under a blind protocol, 
and the effect was assessed by examiners who were 
blinded to the given protocol.
Drugs
Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, 
M.W. 1419), (Diagen, Ljubljana, Slovenia) dissolved 
in saline, was used in all experiments. BPC 157, a 
peptide, is part of the sequence of human gastric juice 
protein BPC, and it is freely soluble in water at pH 7.0 
and saline. The peptide was prepared, as described 
previously[15-25], with 99% high pressure liquid chro-
matography (HPLC) purity, expressing 1-des-Gly 
peptide as an impurity. L-NAME (Sigma, United States) 
and L-arginine (Sigma, United States) were used 
accordingly[1,5,7,17-19,45-51].
Surgical procedure
In deeply anaesthetized rats, an esophagogastric 
anastomosis (PDS 6.0 suture, Johnson & Johnson, 
USA) was created at the apical part of the forestomach 
and distal part of the cut and transferred esophagus.
Experimental protocol
BPC 157 was given perorally, in drinking water (10 
µg/kg, 10 ng/kg, 0.16 µg/mL, 0.16 ng/mL, and 12 
mL/rat per day) until sacrifice, or it was administered 
intraperitoneally (10 µg/kg and 10 ng/kg) with the first 
application at 30 min after surgery, once daily, and the 
last at 24 h before sacrifice.
Combination studies: L-NAME (5 mg/kg intraperito-
neally) and/or L-arginine (100 mg/kg intraperitoneally) 
were given alone or together with the first application 
at 30 min after surgery, once daily, and the last at 24 
h before sacrifice. BPC 157 (10 µg/kg and 10 ng/kg 
intraperitoneally) was given with L-NAME (5 mg/kg 
intraperitoneally) and/or L-arginine (100 mg/kg 
intraperitoneally). Controls simultaneously received an 
equal volume of saline (5.0 mL/kg ip) or water alone. 
The full assessment was performed at days 1, 2, 3, 
and 4, as follows (due to subsequent mortality).
To demonstrate the direct effect of BPC 157 
administration on the blood vessel presentation 
immediately after the creation of esophagogastric 
anastomosis, a bath containing 2 µg/mL of BPC 157 
or a corresponding volume of saline was applied to the 
ventral surface of the stomach. 
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present in the whole stomach (score 3); prominent 
vessels present in the fore stomach (score 4); and 
prominent vessels present in the entire stomach 
(score 5). Continuous camera (Veho discovery 
VMS-004 deluxe) recordings (5 cm above the 
tissue; magnification 30-100 x) were used in deeply 
anesthetized rats for the next 15 min. 
Statistical analysis
Statistical analysis was performed by a non-parametric 
Kruskal-Wallis ANOVA test and, later, a Mann-Whitney 
U-test, to compare groups. The Fisher exact probability 
test was used for mortality assessment. Values of P < 
0.05 were considered statistically significant.
RESULTS
Esophagogastric anastomosis course 
In general, since the beginning, the rats that under-
went esophagogastric anastomosis without medication 
suffered a very severe course (as assessed until post-
operative day 4) that would eventually be lethal 
(at post-operative day 5). These rats had relatively 
small gastric lesions (Figure 1) compared with severe 
esophagitis lesions (Table 1) and poor anastomosis 
(constantly small water volume that could be sus-
tained before leakage) (Figure 2). Considering the 
esophagus at the site of the anastomosis (Figure 3) 
and pyloric sphincter (Figure 4), the pyloric pressure 
seems to be more affected (constantly low pyloric 
sphincter pressure) than the esophageal pressure at 
the anastomotic site. The esophageal pressure was 
initially considerably lower that the lower esophageal 
pressure in normal rats; however, on the fourth day, 
the esophageal pressure approached to that values. 
These changes, however, shortly preceded the lethal 
outcome on post-operative day 5. Meanwhile, these 
rats suffered considerable weight loss. 
BPC 157 therapy: On the other hand, the effect of 
BPC 157 (both µg- and ng regimens, intraperitoneal 
and drinking water applications) seems to be important 
considering the severe and perilous course without it, 
after rats underwent esophagogastric anastomosis. 
Gastric lesions (Figure 1) and esophagitis lesions 
(Table 1) were attenuated, and anastomoses were 
strengthened (water volume before anastomosis 
leakage was more than two times that in the controls) 
(Figure 2); the pressure in the esophagus at the site 
of the anastomosis (Figure 3) and pyloric sphincter 
(Figure 4) markedly increased. Lethal outcomes were 
completely avoided (Fisher exact probability test vs 
control P < 0.05). Weight loss was attenuated (Figure 5). 
L-arginine therapy: Rats that underwent esopha-
gogastric lesions and were treated with L-arginine had 
an attenuated course. Gastric (Figure 1) and esophagitis 
lesions (Table 1) were attenuated and anastomosis was 
Assessment of esophageal and gastric lesions and 
anastomosis
A precise caliper was used to verify the final size of the 
stomach lesions and largest diameter of the gastric 
lesions (mm)[53-55]. The esophagitis scoring[20-23] was 
modified to a 0-5 scoring system, normal, glistening 
mucosa (score 0); edematous mucosa with focal 
hemorrhagic spots (score 1); multiple erosions with 
hematins attached (score 2); tiny esophagus with 
hemorrhagic and linear yellowish lesions (score 3); 
tiny esophagus with coalesced hemorrhagic and 
yellowish lesions (score 4); and tiny esophagus with 
coalesced hemorrhagic, yellowish lesions and dehiscent 
anastomosis (score 5), which was also photographed 
and further verified using the program ISSA (VAMSTEC 
Software Company, Zagreb, Croatia), as described 
previously[1-7]. The tissue was placed in 10% formalin 
and used for histopathological examination, and 
processed for further microscopic analysis[1-7]. 
To assess anastomosis leakage, a separate group 
of animals received a volume of water intragastrically 
to induce leakage[17].
Pressure in the esophagus at the site of anastomosis 
assessment and pyloric sphincter pressure assessment
As described previously[17,18,20-23], manometrical 
evaluation (cm H2O) was performed in all rats, with 
a water manometer connected to the drainage port 
of the Foley catheter, as previously described (values 
of 68-76 cm H2O for the lower esophageal sphincter, 
and 68-74 cm H2O for the pyloric sphincter, were 
considered normal)[17,18,20-23]. The proximal side of the 
esophageal incision, or distal side of the duodenal 
incision, was ligated to prevent regurgitation[17,18,20-23].
Weight assessment
As described in prior works[13,18], animals were weighed 
before surgery, once daily thereafter, and before 
sacrifice. Weight loss (g) was presented as the Δ 
between the initial and final weight[13,18]. 
Mortality
In separate group of animals, mortality was assessed daily 
until post-operative day 7, as described previously[13,18]. 
Very early effects: disappearance of blood vessels at the 
stomach surface in rats that underwent esophagogastric 
anastomosis 
For disappearance and presentation of blood vessels 
at the stomach surface in rats that underwent eso-
phagogastric anastomosis, we described blood vessel 
presentation at the ventral stomach surface (scored 
0-5) throughout stomach distension and/or alcohol 
instillation into the stomach[53], as follows: presentation 
completely reduced, only the main tree of the left 
gastric artery present (score 0); thin vessels present in 
the fore stomach only (score 1); thin vessels present 
in the entire stomach (score 2); moderate vessels 
Djakovic Z et al . Esophagogastric anastomosis, L-NAME, L-arginine, BPC 157
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strengthened (more water volume before anastomosis 
leakage than in controls) (Figure 2). The pressures in 
the esophagus at the site of the anastomosis (Figure 
3) and pyloric sphincter (Figure 4) markedly increased. 
Lethal outcomes were completely avoided (Fisher exact 
probability test vs control, P < 0.05). Weight loss was 
continuously attenuated before the last day (Figure 5). 
L-NAME therapy: Rats that underwent esophago-
gastric lesions and treated with L-NAME had an 
aggravated course. Gastric (Figure 1) and esophagitis 
lesions (Table 1) constantly worsened; other distur-
bances were less expressed. For instance, weakened 
anastomosis constantly sustained a small volume 
water before anastomosis leakage such as in controls 
Figure 1  Gastric lesions, sum of the longest lesions diameters, mean ± SD, mm, in rats that underwent esophagogastric anastomosis. Medication (/kg) 
given intraperitoneally (ip) (once time daily) or continuously in drinking water (po) after the creation of an esophagogastric anastomosis in rats. BPC 157 (10 µg, 10 
ng), L-NAME (5 mg), and L-arginine (100 mg) given alone and/or combined intraperitoneally with the first application at 30 min after anastomosis creation and the last 
at 24 h before sacrifice. Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg, 10 ng/kg; 0.16 µg, 0.16 ng/mL) was provided continuously until 
sacrifice. aP < 0.05, at least, vs control. 
Figure 2  Anastomosis strength. Water volume that could be sustained before leakage, mean ± SD, mL, in rats that underwent esophagogastric anastomosis. 
Medication (/kg) given intraperitoneally (ip) (once time daily) or continuously in drinking water (po) after the creation of esophagogastric anastomosis in rats. BPC 
157 10 µg and 10 ng, L-NAME 5 mg, and L-arginine 100 mg given alone and/or combined intraperitoneally with the first application at 30 min after anastomosis 
creation and last at 24 h before sacrifice. Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg, 10 ng/kg; 0.16 µg, 0.16 ng/mL) was provided 
continuously until sacrifice. aP < 0.05, at least, vs control.
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(Figure 2); there was small pressure in the esophagus 
at the site of the anastomosis (Figure 3) and in 
the pyloric sphincter (Figure 4); and weight loss 
increased on post-operative days 1 and 4 (Figure 5). 
However, they could not survive post-operative day 4 
(Fisher exact probability test vs control P < 0.05, at 
least). 
Combined therapies: L-NAME-induced worsening 
was commonly reversed with medication combinations 
(L-NAME + L-arginine; L-NAME + BPC 157; and 
L-NAME + L-arginine + BPC 157). Gastric (Figure 
1) and esophagitis lesions (Table 1) were constantly 
attenuated. However, in particular, L-NAME + L-arginine 
rats do not immediately have increased anastomosis 
Figure 3  Pressure in the esophagus at the anastomosis site. Mean ± SD, cmH2O, in rats that underwent esophagogastric anastomosis. Medication (/kg) given 
intraperitoneally (ip) (once time daily) or continuously in drinking water (po) after the creation of esophagogastric anastomosis in rats. BPC 157 10 µg and 10 ng, 
L-NAME 5 mg, and L-arginine 100 mg given alone and/or combined intraperitoneally with the first application at 30 min after anastomosis creation and last at 24 h 
before sacrifice. Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg, 10 ng/kg; 0.16 µg, 0.16 ng/mL) was provided continuously until sacrifice. 
aP < 0.05 at least vs control. The values of 68-76 cm H2O for the lower esophageal sphincter were considered to be normal, as determined previously[17,18,20-23].
Figure 4  Pressure in the pyloric sphincter. Mean ± SD, cmH2O, in rats that underwent esophagogastric anastomosis. Medication (/kg) given intraperitoneally 
(ip) (once time daily) or continuously in drinking water (po) after the creation of esophagogastric anastomosis in rats. BPC 157 10 µg and 10 ng, L-NAME 5 mg, and 
L-arginine 100 mg given alone and/or in combination intraperitoneally with the first application at 30 min after anastomosis creation and last at 24 h before sacrifice. 
Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg, 10 ng/kg; 0.16 µg, 0.16 ng/mL) was provided continuously until sacrifice. aP < 0.05, at 
least vs control. The values of 68-74 cm H2O for pyloric sphincter were considered normal, as previously determined[17,18,20-23].
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strength (they develop it later), and pressure in the 
esophagus at anastomosis site and in pyloric sphincter 
is only occasionally increased (Figures 2, 3 and 4). 
Weight loss initially remained increased; then, it was 
reversed to control values (Figure 5). In rats that 
additionally received BPC 157 (L-NAME + BPC 157 
and L-NAME + L-arginine + BPC 157), as well as rats 
treated with L-arginine + BPC 157), these parameters 
were constantly improved. Lethal outcomes were 
commonly avoided (Fisher exact probability test vs 
control P < 0.05, at least). 
Generally, the described macroscopical healing 
(Figure 6) is along with microscopic presentation 
followed and thereby counteracted as described above 
(Figures 7 and 8). In the period after esophagogastric 
anastomosis creation, at the site of anastomosis, 
the control animals showed severe necrosis along 
the anastomosis line, including a large necrotic 
Figure 5  Weight loss (g) presented as the Δ between the initial and final weights[13,18], mean ± SD, in rats that underwent esophagogastric anastomosis. 
Medication (/kg) given intraperitoneally (once time daily) or continuously in drinking water after the creation of an esophagogastric anastomosis in rats. BPC 157 10 
µg and 10 ng, L-NAME 5 mg, and L-arginine 100 mg given alone and/or combined intraperitoneally with the first application at 30 min after anastomosis creation and 
the last at 24 h before sacrifice. Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg and 10 ng/kg; 0.16 µg and 0.16 ng/mL) was provided 
continuously until sacrifice. aP < 0.05, at least, vs control. 
Table 1  Esophagitis score (0-5) Min/Med/Max in rats that underwent esophagogastric anastomosis
Medication (/kg) given ip (once time daily) or 
continuously in drinking water (po) after the creation 
of esophagogastric anastomosis in rats
Esophagitis score (0-5) Min/Med/Max in rats that underwent esophagogastric anastomosis
1 d 2 d 3 d 4 d
Min/Med/Max Min/Med/Max Min/Med/Max Min/Med/Max
Saline 5 mL 4/4/4 4/4/4 4/4/4 4/4/4
BPC 157 10 µg  0/1/2a  0/1/2a  0/1/2a  0/1/2a
L-NAME 5 mg  5/5/5a  5/5/5a  5/5/5a  5/5/5a
L-arginine 100 mg  0/1/2a  1/2/3a  1/2/3a  1/2/3a
L-NAME 5 mg + L-arginine 100 mg  2/3/4a  0/1/2a  1/2/3a  1/2/3a
L-NAME 5 mg + BPC 157 10 µg  1/2/3a  1/2/3a  0/1/2a  0/1/2a
L-arginine 100 mg + BPC 157 10 µg  0/1/2a  0/1/2a  0/1/2a  0/1/2a
L-NAME 5 mg + L-arginine 100 mg +BPC 157 10 µg  0/1/2a  0/1/2a  1/2/3a  0/1/2a
BPC 157 10 ng  0/1/2a  0/1/2a  0/1/2a  0/1/2a
L-NAME 5 mg + BPC 157 10 ng  1/2/3a  2/3/4a  1/2/3a  0/1/2a
L-arginine 100 mg + BPC 157 10 ng  0/1/2a   0/1/2 a  0/1/2a  0/1/2a
L-NAME 5 mg + L-arginine 100 mg +BPC 157 10 ng  1/2/3a  0/1/2a  1/2/3a  0/1/2a
Drinking water 4/4/4 4/4/4 4/4/4 4/4/4
12 mL/d per rat 
   BPC 157 10 µg  0/1/2a  0/1/2a 0/1/2a  0/1/2a
   BPC 157 10 ng  0/1/2a  0/1/2a 0/1/2a  0/1/2a
Medication (/kg) given intraperitoneally (ip) (once daily) or continuously in drinking water (po) after the creation of an esophagogastric anastomosis in 
rats. BPC 157 10 µg and 10 ng, L-NAME 5 mg, and L-arginine 100 mg given alone and/or combined intraperitoneally with the first application at 30 min 
after anastomosis creation and the last at 24 h before sacrifice. Drinking water alone (12 mL/d per rat) or BPC 157 in drinking water (10 µg, 10 ng/kg; 0.16 
µg, 0.16 ng/mL) was provided continuously until sacrifice. aP < 0.05, at least vs control.  
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area of the superficial epithelium and broad band of 
necrotic subcutaneous tissue and muscle. Abundant, 
predominantly polymorphonuclear infiltration was 
present along the anastomosis. The inflammation 
extended to the adipose tissue. Grossly, regular 
confluent hemorrhagic and yellowish lesions appear 
in advanced esophagitis; microscopically, ulcerations 
with pronounced subepithelial and muscular edema, 
Figure 6  Illustrative gross presentation of rats that underwent esophagogastric anastomosis at post-operative day 4 and then received medication saline 
(control, C), BPC 157 (B), or L-NAME (N). 
Figure 7  Illustrative microscopic presentation in rats that underwent 
esophagogastric anastomosis at post-operative day 2, hematoxylin eosin 
staining. Separated anastomosis edges (red arrows) with neutrophils within the 
edges (yellow arrow) were consistently noted in controls (c). Separated wound 
edges (red arrows). Connected edges in rats that underwent esophagogastric 
anastomosis and treated with BPC 157 regimens (black arrow) (b). 
Figure 8  Illustrative microscopic presentation in rats that underwent 
esophagogastric anastomosis at post-operative day 4 [controls (c), 
BPC 157 (b)] and at post-operative day 7 [BPC 157 (B)], hematoxylin 
eosin staining. Tissue destruction at the anastomosis edges (arrows) were 
consistently noted in controls (c), which is a presentation that precedes lethal 
outcome. Initial organization of the exudate (b) (arrows) and wound completely 
closed with granulation tissue (B) (arrows), which is consistently noted in rats 
that underwent esophagogastric anastomosis and were treated with BPC 157. 
Djakovic Z et al . Esophagogastric anastomosis, L-NAME, L-arginine, BPC 157
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mononuclear infiltration, thinner epithelium and super­
ficial corneal layers are present. Gastric mucosal 
lesions mostly presented with hemorrhagic lesions 
that were surrounded by edema of the lamina propria 
and submucosa with a mixed inflammatory reaction. 
However, some presented with extensive necrosis to 
all parts of the mucosa, and they had sharp edges with 
infiltrated granulocytes at the bases.
Very early findings: The following very early findings 
could likely be illustrative of all post-operative courses. 
In control rats that underwent esophagogastric ana-
stomosis immediately after anastomosis creation 
and saline bath application at the ventral side of the 
stomach, blood vessels disappeared from the rat 
gastric surface, lasting for at least 15 min (scored Min/
Med/Max 0/0/0), a period that was carefully monitored 
(Figure 9). Conversely, immediately after anastomosis 
creation and BPC 157 bath application, blood vessels 
did not disappear from the rat gastric surface; these 
vessels remained present, at least during the next 
15 min of monitoring (scored Min/Med/Max 5/5/5, vs 
control P < 0.05) (Figure 9). 
DISCUSSION
We report on the curative treatment of esophagogastric 
anastomosis in rats with stable gastric pentadecapeptide 
BPC 157[1-7]. It was highly successful against a perilous 
and mortal course even when it had to be markedly 
aggravated by L-NAME application. Namely, as observed 
before, rats undergoing esophagogastric anastomosis are 
severely affected[29,30]. They exhibited failed anastomosis 
healing[30,31], but they also presented with progressive 
esophagitis and gastric lesions, leakage, failed pressure 
within the anastomosis site that was markedly below 
values noted in the rat’s lower esophageal sphincter, a 
dysfunctional pyloric sphincter, weight loss, a short-life, 
and inescapable lethal outcomes. 
As mentioned, BPC 157 treatment along with an 
NO-synthase (NOS) blocker, L-NAME, nullified any 
effect of L-NAME that would otherwise markedly 
intensify the regular course. Consistently, with 
worsening (obtained with L-NAME administration) 
and amelioration (with L-arginine), either L-arginine-
amelioration prevails (i.e., esophageal and gastric 
lesions attenuated) or they counteract each other 
(L-NAME + L-arginine) with an effect that was further 
reversed toward a marked beneficial effect by the 
addition of BPC 157 (L-NAME + L-arginine + BPC 157). 
Together, these provide evidence for an innate NO-
system disability (L-NAME-worsening) that could be 
corrected by the administration of a NOS substrate, 
such as L-arginine, and almost completely eliminated 
by BPC 157 therapy. Accordingly, in various models 
and species[1,5,7,17,18,20,45-51], BPC 157 counteracted the 
L-NAME effect better than L-arginine[1,5,7,17,18,20,45-51] as 
well as induced NO-release in the gastric mucosa from 
rat stomach tissue homogenates, even in conditions 
in which L-arginine is not working[50,56]. No further 
beneficial effect was observed when BPC 157 and 
L-arginine were co-administered[1,5,7,17,18,20,45-51]. 
In the rats that underwent esophagogastric anas-
tomosis, the particular point of BPC 157 effectiveness 
involving both anastomosis healing and sphincter 
rescue was the realized anastomosis creation already 
in controls that at least partly rescued the sphincter 
function at the site of anastomosis, while pressure in 
the pyloric sphincter remains constantly low. Of note, 
pylorus sphincter failure was thought to reflect lower 
esophageal sphincter failure[17,18,20-23]. This was further 
additionally improved in rats that underwent BPC 157 
therapy, and pressure in the pyloric sphincter is also 
rescued, which is an important point now reported. 
Previously, we demonstrated that BPC 157 maintains 
sphincter function (lower esophageal, pyloric[17,18,20-23], 
Figure 9  Blood vessels presentation at the ventral site of the stomach surface in rats that just underwent esophagogastric anastomosis. In general, 
immediately after anastomosis creation and saline bath application, blood vessels disappeared from the rat gastric surface, and this effect lasts at least the next 15 
min (scored Min/Med/Max 0/0/0), a period that was carefully monitored (control, c). With a BPC 157 bath immediately after anastomosis creation, the blood vessels 
did not disappear from the rat gastric surface; instead, these vessels remained present during at least the next 15 min of monitoring (BPC 157, b).
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urethral[24], and pupil[25]). Specifically, simultaneous 
lower esophageal and pyloric sphincter function 
assessment, as a hallmark of reinstated function and 
tissue integrity[17,18,20-23], demonstrates that when there 
are more lesions present, the sphincter pressure is 
lower[17,18,20-23]. Of note, BPC 157 therapy regularly 
counteracted the disability of the lower esophageal and 
pyloric sphincter[17,18,20-23], induced in various ways (i.e., 
stretching sphincters with temporal tube insertion[21-23], 
potassium chloride overdose application[20], bile duct 
ligation-induced pancreatitis[21], esophagocutaneous[18] 
or duodenocutaneous fistula creation[17], and lower 
esophageal sphincter dysfunction instantly induced 
pyloric sphincter failure, and vice versa[21-23]). In fistula 
conditions, this was shown to be a NO-system related 
phenomenon[7,17,18]. With respect to the outcome 
of esophagogastric anastomosis, an interesting 
anastomosis analogy could be made, providing that 
these surgically created fistulas are actually anastomosis 
between two different tissues (i.e., esophagus and 
skin[17]; duodenum and skin[18]; colon and skin[7]) and, 
thereby, sphincter function rescue could be observed 
along with anastomoses healing. 
Of note, indicatively, anastomosis creation that 
better rescued the sphincter function at the site of 
anastomosis (as well as the pyloric sphincter function) 
could be also obtained in L-arginine-treated rats. 
Additionally, sphincter failure is proposed as a hallmark 
of ongoing injury[17,18,20-23] along with an injurious effect 
of L-NAME itself[1,5,7,17,18,20,45-51] that overrides previous 
considerations about NO-sphincter relationships[57] while 
being unrelated to injurious conditions (i.e., in dogs, 
ferrets and muscle strips[58-60]). In rats that underwent 
esophagogastric anastomosis and L-NAME therapy, 
the final drop of pressure within the esophagus at the 
site of anastomosis on day 4 occurs just prior to death. 
Here, moreover, we have to assume dysfunction of the 
nitrergic pathway; for instance, excision-immediate 
heavy loss of endothelium cells from the vascular wall 
results in a lower NO-production ability[61], which has 
different action for the damaged tissue integrity.
Thereby, in rats with esophagogastric anastomosis 
that were treated with L-NAME, the degree of sphincter 
failure was higher, in accordance with the worst 
esophageal and gastric lesions, and accelerated lethal 
outcomes. 
Finally, it is reasonable to assume also in the 
esophagogastric anastomosis studies that constant 
vessel presentation could predict the beneficial effect 
of the applied agent[53]. Thereby, it is interesting 
to note the perilous effect of ischemia[31-33] and, 
conversely, angiogenesis in improving esophagogastric 
anastomosis healing triggered in the conditioned 
stomach (partial stomach devascularization)[34-37], 
as evidenced in a period of one week[34-37]. These 
observations have to be further corroborated with 
the noted beneficial effect of BPC 157 in rats with 
esophagogastric anastomosis. Namely, BPC 157 
exhibits a rapid, beneficial effect (since the first day), 
and BPC 157 is a cytoprotective agent[1-7,38,53] that 
rapidly induces strong endothelium protection[38] and 
prominent angiogenic effects (seen when placed 
in the classic sponge inserted into the rat’s back 
or through various tissues healing[2,40,62] with VGEF 
expression[2,40,62]). As a result, BPC 157 obviously has 
an additional, more direct beneficial effect on blood 
vessel presentation[1-7,38,40,53,62]. 
The constant vessel presentation synergizes the 
beneficial effect of BPC 157[53], and it is worth noting 
that after pentadecapeptide BPC 157 instillation into 
the stomach following distension or alcohol instillation 
into the stomach, the vessel presentation remains 
constant, while left gastric artery blood vessels 
clearly disappear at the serosal site, indicative of 
loss in the integrity and function within a minute[53]. 
These findings[53] correlate with the findings noted 
immediately after the creation of esophagogastric 
anastomosis in rats, wherein left gastric artery blood 
vessels clearly disappear at the serosal site, unlike the 
constant vessel presentation in rats that underwent 
BPC 157 therapy. This may be an early, essential point 
for achieving the further full healing effect. 
The esophagogastric anastomosis point provides the 
anastomosis strength (i.e., with various anastomosis 
leakage, the highest rates belong to this anastomotic 
leakage alone[8,9]). Since the very beginning, stable 
gastric pentadecapeptide BPC 157 significantly improved 
all parameters of anastomotic wound healing in rats 
with esophagogastric anastomosis, as has previously 
been shown with various intestinal anastomoses[10-14] 
(note BPC 157 also improves the blood vessel and 
peripheral nerve anastomoses[63,64]), and with both 
external and internal fistulas[7,15-19], which were ori-
ginally created as the surgical anastomoses between 
various tissues[7,15-19]. As a result, BPC 157 especially 
improves the anastomotic strength. Furthermore, 
we noted comparable, complex functional and 
biomechanical improvement of various tissues[65-68], as 
well as their suitable healing and functional restoration 
(i.e., increased tensile breaking force, relative 
elongation of the burned skin[65,66], failure of the load 
of the transected tendon[67] or muscle[68], improved 
walking[67,68], and absent post-injury contracture[67,68]). 
Therefore, since these results were obtained with the 
same dosage regimen, increased tensile strength of 
the anastomosis is a direct reflection of the successful 
repair process[69], and an essential healing point[1-7,53] 
could be achieved along with the stimulation of the 
early growth response-1 (EGR-1) gene and its co-
repressor nerve growth factor 1-A binding protein-2 
(NAB2), cytokine and growth factor generation 
and thereby, early extracellular matrix (collagen) 
and blood vessel formation[41], and other molecular 
pathways[41-44].
These processes may be involved in a particular 
feedback-process for the simultaneous healing of 
different tissues, which can improve esophagogastric 
anastomosis healing and counteract all consequences 
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of an otherwise fatal injury course.
In addition, for a new NO-system phenomenon, 
stable gastric pentadecapeptide BPC 157, along with 
NOS-blockade, L-NAME, and NOS-substrate L-arginine 
application[1], would favorably define esophagogastric 
anastomosis healing, esophagitis and gastric defect 
healing, as well as rescue the “sphincter” pressure at 
the site of anastomosis while preserving the pyloric 
sphincter pressure. These approaches should be used 
to counteract the frequently dangerous course after 
esophagogastric anastomosis creation.
COMMENTS
Background
BPC 157 treatment of esophagogastric anastomosis along with a NO-synthase 
(NOS) blocker, L-NAME, and/or NOS substrate L-arginine would evidence an 
innate NO-system disability, and investigate the effect on the corresponding 
worsening (obtained with L-NAME administration) or amelioration (due to 
L-arginine).
Research frontiers
BPC 157 treatment of esophagogastric anastomosis along with a NO-synthase 
(NOS) blocker, L-NAME, and/or NOS substrate L-arginine would evidence an 
innate NO-system disability, and investigate the effect on the corresponding 
worsening (obtained with L-NAME administration) or amelioration (due to 
L-arginine).
Innovations and breakthroughs
The stable gastric pentadecapeptide BPC 157, was given daily, intraperitoneally 
or orally, in drinking water, using the previous efficacious regimens. In 
addition to these effects, the possible simultaneous healing (stable gastric 
pentadecapeptide BPC 157, along with both NOS-blockade, L-NAME, and 
NOS-substrate L-arginine application) would define the esophagogastric 
anastomosis healing, define esophagitis and gastric defects healing, rescue 
“sphincter” pressure at the site of anastomosis and preserve pyloric sphincter 
pressure, as a new NO-system related phenomenon.
Applications
A new NO-system phenomenon, stable gastric pentadecapeptide BPC 157, 
along with NOS-blockade, L-NAME, and NOS-substrate L-arginine application[1], 
would favorably define esophagogastric anastomosis healing, esophagitis 
and gastric defect healing, as well as rescue the “sphincter” pressure at the 
site of anastomosis while preserving the pyloric sphincter pressure. These 
approaches should be used to counteract the frequently dangerous course after 
esophagogastric anastomosis creation.
Peer-review
This manuscript presents stable gastric pentadecapeptide BCP157, along 
with NOS-blockade, L-NAME, and NOS-substrate L-argnine application would 
favorably define the esophagogastric anastomosis healing, esophagitis and 
gastric defects healing and rescued sphincter pressure.
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